From the Guidelines
The provided question does not form a coherent medical inquiry due to the misuse of medical terminology, making it impossible to provide a clinically relevant answer based on current medical evidence. The phrase "MDs gain of chromosome 179F gfr 3/4" combines terms in a way that doesn't align with standard medical language or measurements. Normally, GFR (glomerular filtration rate) is measured in terms of milliliters per minute per 1.73 square meters (mL/min/1.73 m^2) and is used to assess kidney function, with lower values indicating poorer kidney function 1. Chromosomal abnormalities are typically described in terms of known human chromosomes (1-22, X, and Y), and "179F" does not correspond to any recognized human chromosome designation.
Given the information provided in the evidence about chronic kidney disease (CKD) and its management, it's clear that CKD is defined by either kidney damage or decreased kidney function (decreased GFR) for 3 or more months, and early detection and treatment can prevent or delay adverse outcomes 1. However, without a clear and medically accurate question, it's not possible to apply this knowledge to provide a specific recommendation.
If the question is intended to inquire about the implications of a GFR of 3/4 (which is not a standard way to express GFR), or about chromosomal abnormalities in relation to kidney function, it would be necessary to rephrase the question with accurate medical terminology to receive a relevant and evidence-based answer. The current evidence supports the importance of monitoring and managing kidney function to prevent complications such as cardiovascular disease, which is a significant concern in patients with CKD 1.
From the Research
MDs Gain of Chromosome 179F GFR 3/4
- The provided studies do not directly address the topic of MDs gain of chromosome 179F GFR 3/4.
- However, some studies discuss the importance of genetic testing in diagnosing and managing chronic kidney disease (CKD) 2, 3, 4.
- A study published in 2022 found that genetic testing using a kidney gene panel can help identify pathogenic variants for monogenic diseases, which can inform diagnosis and management 2.
- Another study published in 2023 found that genetic testing with a 385 gene kidney disease panel can refine clinical diagnoses and have implications for clinical management, including treatment strategies 3.
- A study published in 2022 also found that broad gene panels can provide unbiased testing approaches, which are advantageous in phenotypically heterogeneous diseases such as CKD 4.
- The studies suggest that genetic testing can be a valuable tool in diagnosing and managing CKD, but do not specifically address the topic of MDs gain of chromosome 179F GFR 3/4.
Genetic Testing in CKD
- Genetic testing can help identify the underlying cause of CKD, which can influence management and overall health 3.
- A study found that genetic testing with a 385 gene kidney disease panel can provide a new or reclassified diagnosis in 48.8% of patients with positive genetic findings 3.
- Genetic testing can also inform treatment strategies, with 32.9% of patients with positive genetic findings experiencing changes in treatment plan 3.
- The use of broad panel genetic testing by clinical nephrologists has been shown to have a high success rate, similar to results obtained by academic centers specializing in genetics 4.
CKD Diagnosis and Management
- CKD is a major public health issue, and identification of monogenic causes can impact prognosis and patient management 4.
- Appropriate screening, diagnosis, and management by primary care clinicians are necessary to prevent adverse CKD-associated outcomes 5.
- Optimal management of CKD includes cardiovascular risk reduction, treatment of albuminuria, avoidance of potential nephrotoxins, and adjustments to drug dosing 5.